Kaia Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 34)
Kaia Health logo

Kaia Health

EmergingHealthTech

Digital Therapeutics

Kaia Health delivers AI-guided digital physical therapy for musculoskeletal pain via smartphone, using motion tracking to coach patients through personalized exercise programs.

AI VisibilityBeta
Overall Score
D34
Category Rank
#591 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
37
Gemini
31

About

Kaia Health's digital therapeutics app uses a smartphone camera and computer vision to track patient movement in real time, providing guided exercise therapy for back pain, hip pain, and COPD without requiring wearable sensors or in-person physical therapy visits. The AI coach analyzes posture and movement quality, providing real-time feedback and adjusting program difficulty as patients improve — replicating key elements of supervised PT in an app-based, self-directed format.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

34
Overall Score
81
#591
Category Rank
#17
74
AI Consensus
71
stable
Trend
stable
40
ChatGPT
80
37
Perplexity
75
31
Gemini
77
37
Claude
86
30
Grok
85

Key Details

Category
Digital Therapeutics
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Kaia Health
Digital Therapeutics

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.